We are live on ! Find out more
LEXXW

Lexaria Bioscience Warrant
LEXXW

Delisted

LEXXW was delisted on the 13th of January, 2026.

Back to rankings

3 hedge funds and large institutions have $389K invested in Lexaria Bioscience Warrant in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $303K → $389K (+$86.1K)

25% less funds holding

Funds holding: 4 → 3 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$23.9K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$215K – – –
SM
2
Sabby Management
Florida
$150K +$23.9K +43,385 +20%
CH
3
CVI Holdings
Delaware
$24.2K – – –
Citadel Advisors
4
Citadel Advisors
Florida
– -$4.2K -10,496 Closed

LEXXW Hedge Fund Activity: Q1 2023 in Review

3 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q1 2023, worth a combined $389K — up 28% from $303K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of LEXXW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Sabby Management, adding an estimated $23.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $4.2K sold.

  • 3 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q1 2023, down from 4 in Q4 2022.
  • Funds reported $389K of Lexaria Bioscience Warrant stock for Q1 2023, up 28% quarter-over-quarter.
  • 0 funds opened new Lexaria Bioscience Warrant positions in Q1 2023 and 1 closed out, a net change of -1 holder.
  • The largest Lexaria Bioscience Warrant buyer in Q1 2023 was Sabby Management, an estimated $23.9K added.
  • The largest Lexaria Bioscience Warrant seller in Q1 2023 was Citadel Advisors, an estimated $4.2K sold.

Based on aggregated 13F filings for Q1 2023.